Analysis of Survivin-Specific T Cells in Breast Cancer Patients Using Human DCs Engineered with Survivin mRNA

Ozcan Met; Inge Marie Svane

doi:10.1007/978-1-62703-260-5_17

Analysis of Survivin-Specific T Cells in Breast Cancer Patients Using Human DCs Engineered with Survivin mRNA

3 Citations (Scopus)

Abstract

The observation that dendritic cells (DCs) charged with tumor-associated antigens (TAAs) is a potent strategy to elicit protective immunity in tumor-bearings hosts has prompted extensive testing of DCs as cellular adjuvant in cancer vaccines. To improve the clinical development of DC-based cancer vaccines, it may be beneficial to analyze preexistent immunity against TAAs in cancer patients because it may be easier to expand a memory pool of T cells compared to generating new immunity. Recent research shows that engineering DCs to synthesize tumor epitopes endogenously by transfecting DCs with mRNA-encoding TAAs are particular effective in stimulating robust T-responses in vitro and in vivo. In this chapter, we describe the methodology to analyze for survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNA.

Original language	English
Journal	Methods in Molecular Biology
Volume	969
Pages (from-to)	275-92
Number of pages	18
ISSN	1064-3745
DOIs	https://doi.org/10.1007/978-1-62703-260-5_17
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-1-62703-260-5_17

Cite this

@article{610cae2d0f5041fb9fb779bbe41d812d,

title = "Analysis of Survivin-Specific T Cells in Breast Cancer Patients Using Human DCs Engineered with Survivin mRNA",

abstract = "The observation that dendritic cells (DCs) charged with tumor-associated antigens (TAAs) is a potent strategy to elicit protective immunity in tumor-bearings hosts has prompted extensive testing of DCs as cellular adjuvant in cancer vaccines. To improve the clinical development of DC-based cancer vaccines, it may be beneficial to analyze preexistent immunity against TAAs in cancer patients because it may be easier to expand a memory pool of T cells compared to generating new immunity. Recent research shows that engineering DCs to synthesize tumor epitopes endogenously by transfecting DCs with mRNA-encoding TAAs are particular effective in stimulating robust T-responses in vitro and in vivo. In this chapter, we describe the methodology to analyze for survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNA.",

author = "Ozcan Met and Svane, {Inge Marie}",

year = "2013",

doi = "10.1007/978-1-62703-260-5_17",

language = "English",

volume = "969",

pages = "275--92",

journal = "Methods in Molecular Biology",

issn = "1064-3745",

publisher = "Humana Press",

}

TY - JOUR

T1 - Analysis of Survivin-Specific T Cells in Breast Cancer Patients Using Human DCs Engineered with Survivin mRNA

AU - Met, Ozcan

AU - Svane, Inge Marie

PY - 2013

Y1 - 2013

N2 - The observation that dendritic cells (DCs) charged with tumor-associated antigens (TAAs) is a potent strategy to elicit protective immunity in tumor-bearings hosts has prompted extensive testing of DCs as cellular adjuvant in cancer vaccines. To improve the clinical development of DC-based cancer vaccines, it may be beneficial to analyze preexistent immunity against TAAs in cancer patients because it may be easier to expand a memory pool of T cells compared to generating new immunity. Recent research shows that engineering DCs to synthesize tumor epitopes endogenously by transfecting DCs with mRNA-encoding TAAs are particular effective in stimulating robust T-responses in vitro and in vivo. In this chapter, we describe the methodology to analyze for survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNA.

AB - The observation that dendritic cells (DCs) charged with tumor-associated antigens (TAAs) is a potent strategy to elicit protective immunity in tumor-bearings hosts has prompted extensive testing of DCs as cellular adjuvant in cancer vaccines. To improve the clinical development of DC-based cancer vaccines, it may be beneficial to analyze preexistent immunity against TAAs in cancer patients because it may be easier to expand a memory pool of T cells compared to generating new immunity. Recent research shows that engineering DCs to synthesize tumor epitopes endogenously by transfecting DCs with mRNA-encoding TAAs are particular effective in stimulating robust T-responses in vitro and in vivo. In this chapter, we describe the methodology to analyze for survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNA.

U2 - 10.1007/978-1-62703-260-5_17

DO - 10.1007/978-1-62703-260-5_17

M3 - Journal article

C2 - 23296940

SN - 1064-3745

VL - 969

SP - 275

EP - 292

JO - Methods in Molecular Biology

JF - Methods in Molecular Biology

ER -

Analysis of Survivin-Specific T Cells in Breast Cancer Patients Using Human DCs Engineered with Survivin mRNA

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this